Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

NCT05904691 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration (nAMD)

Interventions

DRUG: OCU-10-C-110 for Injection

Sponsor

Ocugenix Corporation